UNIVERSITY COLLEGE LONDON

Upperton Pharma Solutions has secured funding from the VaxHub Sustainable Platform Funding Call to develop an oral formulation for adenovirus-vectored vaccines in collaboration with the University of Oxford.

Qualigen Therapeutics has been granted new patents covering QN-302, a cancer drug candidate targeting pancreatic and gastrointestinal cancers, across more than 25 countries including over 20 European nations, India, China, and Russia.

AstraZeneca's CARES Phase III clinical programme evaluating anselamimab in patients with Mayo stages IIIa and IIIb light chain amyloidosis did not achieve statistical significance for the primary endpoint of time to all-cause mortality and cardiovascular hospitalizations.

The phase 3b ProvIDHe study demonstrated that ivosidenib achieved a median progression-free survival of 4.7 months and overall survival of 15.5 months in patients with IDH1-mutated cholangiocarcinoma.

Skyhawk Therapeutics has dosed the first patient in its Phase 2/3 FALCON-HD trial evaluating SKY-0515, an oral RNA splicing modulator for Huntington's disease treatment.

The 2025 European Hematology Association Congress featured promising clinical trial results across multiple hematologic cancers, with novel trispecific and bispecific antibodies showing exceptional response rates in challenging patient populations.

A randomized controlled trial involving 292 children across four African countries found that intravenous rehydration was as safe as oral rehydration for children with severe acute malnutrition and gastroenteritis.

A new smartphone-based digital motor score (HDDMS) developed by UCL and Roche researchers demonstrates twice the sensitivity of current clinical measures in detecting Huntington's disease progression.

The phase III AMPLITUDE trial demonstrated that adding niraparib to abiraterone acetate plus prednisone significantly improved radiographic progression-free survival in patients with metastatic castration-sensitive prostate cancer harboring HRR gene alterations.

Researchers developed an AI test that can predict which men with high-risk prostate cancer will benefit most from abiraterone treatment by analyzing tumor images.